Skip to search formSkip to main contentSkip to account menu

CPU0213

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Pyrazoles

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
Sildenafil improves diabetic vascular activity through suppressing endothelin receptor A, iNOS and NADPH oxidase which is comparable with the endothelin receptor antagonist CPU0213 in STZ‐injected…
Objectives  Abnormal vascular activity in diabetes is related not only to impaired nitric oxide bioavailability but also to… 
2010
2010
The separate roles of endothelin receptors participate in remodeling of matrix metalloproteinase and connexin 43 of cardiac fibroblasts in maladaptive response to isoproterenol.
2008
2008
Downregulated FKBP12.6 expression and upregulated endothelin signaling contribute to elevated diastolic calcium and arrhythmogenesis in rat cardiomyopathy produced by l-thyroxin.
2008
2008
Normalizing NADPH Oxidase Contributes to Attenuating Diabetic Nephropathy by the Dual Endothelin Receptor Antagonist CPU0213 in Rats
Background/Aims: NADPH oxidase(NOX) is the main source of reactive oxygen species (ROS) in diabetic nephropathy (DN). Activation… 
2008
2008
The Endothelin Receptor Antagonist CPU0213 is More Effective Than Aminoguanidine to Attenuate Isoproterenol-induced Vascular Abnormality by Suppressing Overexpression of NADPH Oxidas, ETA, ETB, and…
An increase in reactive oxygen species (ROS) through NADPH oxidase activation frequently follows stress that activates… 
2007
2007
UPREGULATED ENDOTHELIN SYSTEM IN DIABETIC VASCULAR DYSFUNCTION AND EARLY RETINOPATHY IS REVERSED BY CPU0213 AND TOTAL TRITERPENE ACIDS FROM FRUCTUS CORNI
1 The aims of the present study were to examine whether: (i) upregulation of the endothelin (ET) pathway is involved in… 
2007
2007
Reversal of isoproterenol-induced downregulation of phospholamban and FKBP12.6 by CPU0213-mediated antagonism of endothelin receptors
AbstractAim:The downregulation of phospholamban (PLB) and FKBP12.6 as a result of β-receptor activation is involved in the… 
2007
2007
Endothelin receptor antagonist CPU0213 suppresses ventricular fibrillation in L-thyroxin induced cardiomyopathy.
Arrhythmias correlate with disorders of either K(2+) channels in sarcolemma or calcium modulating system in sarcoplasmic… 
2006
2006
A Novel Endothelin Receptor Antagonist CPU0213 Improves Diabetic Cardiac Insufficiency Attributed to Up-regulation of the Expression of FKBP12.6, SERCA2a, and PLB in Rats
The depressed sarcoplasmic reticulum (SR) Ca2+-ATPase (SERCA2a) and Ca2+-release channels (ryanodine receptor RyR2) are involved… 
2006
2006
CPU0213, a novel endothelin receptor antagonist, ameliorates septic renal lesion by suppressing ET system and NF-κB in rats
AbstractAim:To examine whether a novel endothelin receptor antagonist, CPU0213, is effective in relieving the acute renal failure… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)